{"id":687604,"date":"2022-09-21T09:47:07","date_gmt":"2022-09-21T13:47:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"modified":"2022-09-21T09:47:07","modified_gmt":"2022-09-21T13:47:07","slug":"palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","title":{"rendered":"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference"},"content":{"rendered":"<h2>\nLive video webcast fireside chat on Thursday, September 29th at 11:30 AM ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">CARLSBAD, Calif., Sept.  21, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g8lXY1d7jXdP2T-KhPwH8fbRpw9O00HWSGMgXEhdpG1W5baPoVOOHRmJJZ890RAto2IY781feSuNsmK5SYCcBdMzZR1oXamSnr1HtsDm36g=\" rel=\"nofollow noopener\" target=\"_blank\">Palisade Bio, Inc.<\/a>\u00a0(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will participate in a fireside chat on Thursday, September 29, 2022 at 11:30 AM ET at the Ladenburg Thalmann 2022 Healthcare Conference in New York, NY.<\/p>\n<p align=\"justify\">In addition to the fireside chat, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_VefFiFsy2cpl7NV-smXmAJgFqZOluDZC4PXj4gug3zghI43mmQHdqpT6BalSMKh9yrXwupdswsLPO3XXJWwaENX5ycTKFvH-u051EV3v__v96DLRrpMmXhha5Ft3Rzp\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">A <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4FFU2oeHAauyPsWjeah66P8osK6v_Y6ngGb62k8r5oFQD3m0tfkzwdmxK2nX6Zsnqw4HA9ouIn4E2JgjuaD7ApCQAyukr6TbR3lZCWuBNygEIBwHkAjzKBJm9o1WoTnO\" rel=\"nofollow noopener\" target=\"_blank\">live video webcast<\/a> of the fireside chat will be available in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EUhC-GKDKXxiYqZ9yg_k4Q13-pP1kHhuqasVkdRayevot2ZBT1wYxhkBwANFI0wQU3jy7UgU_1C-oJFT7Fe8diD5w6Fd2hLdk1j4Z5yPMac=\" rel=\"nofollow noopener\" target=\"_blank\">Events<\/a> section of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Nn2lrjxRjeHMGTMn5UyN6NBptwF-KOPIcT-KiAD0rTSGMnFm-V8Tap58NE3rWHXfjdq0lUqliaaTOg-SY68yGMoTPOTCbNql101ZYxPzKk=\" rel=\"nofollow noopener\" target=\"_blank\">Investors &amp; News<\/a> page of Palisade Bio website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X1RATQJ3AfDxnGsragZILCzDpQW5A3su__e3LExkPG3w1zTNMN_8QMIW2ILIyEIKJmiPPnZad4hOzQ3e2GVjSnxAPtZLx5yC-Or6Lvw09nA=\" rel=\"nofollow noopener\" target=\"_blank\">palisadebio.com<\/a>) and will be accessible for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Palisade Bio\u00a0<br \/><\/strong>Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.<\/p>\n<p align=\"justify\">The Company\u2019s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and the Company recently presented analysis that LB1148 reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a pivotal Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.<\/p>\n<p align=\"justify\">The Company believes that addressing the disruption of the intestinal barrier has the potential to fundamentally change the way diseases are treated and to establish new standards of patient care. For more information, please go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P1UF9f3ue5OUz0Gdl1VT6ARGc-F5EOfSqcBCFatRfK_beU6E5pUY1JckSlXnwy1UarI-YT5-8dFt4Vc0NOZBkPg4iSy2Bj6sGU0QpviEl44=\" rel=\"nofollow noopener\" target=\"_blank\">www.palisadebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This communication contains \u201cforward-looking\u201d statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Palisade\u2019s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential to fundamentally change the way diseases are treated, the completion of enrollment for the Phase 3 study, the potential for the statistically significant Phase 3 data to allow for NDA approval, and the potential for LB1148 to establish the standard of care, if approved. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade\u2019s current expectations. Forward-looking statements involve risks and uncertainties. Palisade\u2019s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the company\u2019s ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the company\u2019s ability to achieve additional financing to fund clinical development and the company\u2019s ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in Palisade Bio\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.\u00a0Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade\u2019s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based<em>.<\/em><\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas <br \/>833-475-8247<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9E-tVrwRB8xy-E2RoWAQQPZqZMRHCFx3HZDNgDejBd-eqdj5FvdDiShw0FHmBMpgp3pZhglkVnZKisCXNLJ2EA==\" rel=\"nofollow noopener\" target=\"_blank\">PALI@jtcir.com<\/a><\/p>\n<p>Source: Palisade Bio<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDRhMDAzNzctODVjYi00ZTAyLTg2NDEtOTYwMzdkYTQ1N2RmLTEwMjIyMzY=\/tiny\/PALISADE-BIO-INC-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET CARLSBAD, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc.\u00a0(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will participate in a fireside chat on Thursday, September 29, 2022 at 11:30 AM ET at the Ladenburg Thalmann 2022 Healthcare Conference in New York, NY. In addition to the fireside chat, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website here. A live &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687604","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET CARLSBAD, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc.\u00a0(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will participate in a fireside chat on Thursday, September 29, 2022 at 11:30 AM ET at the Ladenburg Thalmann 2022 Healthcare Conference in New York, NY. In addition to the fireside chat, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website here. A live &hellip; Continue reading &quot;Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T13:47:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference\",\"datePublished\":\"2022-09-21T13:47:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"},\"wordCount\":619,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\",\"name\":\"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=\",\"datePublished\":\"2022-09-21T13:47:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","og_description":"Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET CARLSBAD, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc.\u00a0(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will participate in a fireside chat on Thursday, September 29, 2022 at 11:30 AM ET at the Ladenburg Thalmann 2022 Healthcare Conference in New York, NY. In addition to the fireside chat, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website here. A live &hellip; Continue reading \"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-21T13:47:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference","datePublished":"2022-09-21T13:47:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"},"wordCount":619,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/","name":"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=","datePublished":"2022-09-21T13:47:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDgyMyM1MTYzNDk1IzIwMTA2NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-present-at-the-ladenburg-thalmann-2022-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687604"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687604\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}